Advertise on podcast: Listen to Gynecologic Oncology

Editor's Choice:  Pregnancies in gynecologic oncologists: An assessment of pregnancy policies and complications within a surgical subspecialty Editorial: Pregnancy complications in gynecologic oncologists – A call to action to do better Hosted by:  Paola Gehrig, MD University of Virginia , Charlottesville,  United States of America Featuring:  Kelsey Goon, MD University of Chicago, United States of America Kathryn A. Mills, MD University of Chicago, United States of America Christine S. Walsh, MD University of Colorado School of Medicine, United States of America Brooke Sanders, MD Washington University School of Medicine, United States of America Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer Editorial: A path to precision in endometrial cancer management: Moving past FIGO 2023 Hosted by:  David Gaffney, MD, PhD The University of Utah, Salt Lake City, Utah, United States of America Featuring:  Allison Roy, MD SUNY Upstate Medical University, Syracuse, NY, United States of America Jessica N. McAlpine University of British Columbia,  Vancouver, BC, Canada David Mutch Washington University School of Medicine, St Louis, MO, United States of America Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update Editorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelines Hosted by:  Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA Featuring:  Gregg Nelson, MD, PhD; Department of Obstetrics & Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Richard D. Urman, MD; Department of Anesthesiology, The Ohio State University Wexner Medical Center and College of Medicine, Columbus, OH, USA Olle Ljungqvist, MD, PhD; Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, Sweden Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial Editorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancer Hosted by:  Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USA Featuring:  Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USA Ramez N Eskander, MD;  Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice Hosted by:  Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USA Featuring:  Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA John B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA Joy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review Moderator: Ursula A. Matulonis, MD; Dana-Farber Cancer Institute Speakers: Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone Health Róisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical College Yvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British Columbia Christina Washington, MD; Stephenson Cancer Center, University of Oklahoma Ursula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O’Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals. The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice. This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients. This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer Editorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection Hosted by:  Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada Featuring:  Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA Alexander Melamed, MD MPH, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA Jose Alejandro Rauh-Hain, MD MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement Hosted by: Jose Alejandro Rauh-Hain, MD MPH Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Featuring: Charles A. Powell, MD, MBA Division of Pulmonary, Critical Care and Sleep Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial Editorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cancer Trials Group Cx.5/SHAPE trial Hosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada Featuring: Janice S. Kwon  MD, MPH, FRCSC, University of British Columbia, Vancouver, Canada and  R. Wendel Naumann, MD Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28203, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment? Editorial: Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USA Christina M. Annunziata, American Cancer Society, Atlanta, GA, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches Editorial: Who is following up? Rethinking survivorship and surveillance Hosted by: Paola A Gehrig, MD University of Virginia Charlottesville, Virginia United States Featuring: Lee-may Chen, MD; Division of Gynecologic Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States Esther Vermaas; Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands J.W.M. Aarts, MD, PhD; Principal Investigator and Gynaecological oncologist Amsterdam University Medical Centers, location VUMC, the Netherland Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant Editorial: Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 carriers:Why is this a question? Hosted by: John Farley, MD, COL(ret), FACOG, FACS, St Joseph's Hospital and Medical Center, Phoenix, AZ, United States of America Featuring: Steven Narod, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada Stephanie Blank, Icahn School of Medicine at Mount Sinai,  New York, NY, USA Melissa K. Frey, Weill Cornell Medicine, New York, NY, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer Editor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer Editorial: From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncology Hosted by: Paola Gehrig, MD, Associate Editor of Gynecologic Oncology Featuring: Bradley Corr, University of Colorado, Aurora, CO, USA Ursula Matulonis, Dana-Farber Cancer Institute, Boston, MA, USA Mary M. Mullen, Washington University School of Medicine, St Louis, MO, USA Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: William Cliby, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA Chiara Ainio, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA Oliver Zivanovic, Clinic for Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S Editorial: Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatment Editorial: Minimum standards for radiation therapy in the treatment of cervical cancer in the U.S.: A consensus statement by SGO, ASTRO, and ABS addressing the WHO Cervical Cancer Elimination Campaign goals Hosted by: Dr. Warner Huh, Associate Editor of Gynecologic Oncology Featuring: Drs. Charles A. Leath, University of Alabama at Birmingham, Birmingham, AL, USA  Junzo Chino, Duke University Medical Center, Durham, NC, USA  Shane Neibart, Brigham and Women's Hospital, Boston, MA, USA Nancy Zhou, Rutgers New Jersey Medical School, Newark, NJ, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net